Home    Back

Egcg as putative neuroprotective agent    (DrugBank: EGCG)

1 disease
IDDisease name (Link within this page)Number of trials
17Multiple system atrophy1

17. Multiple system atrophy    [ 107 clinical trials,   153 drugs,   (DrugBank: 48 drugs),   59 drug target genes,   104 drug target pathways]
Searched query = "Multiple system atrophy", "MSA-C", "MSA-P", "Olivopontocerebellar atrophy", "OPCA", "Striatonigral degeneration", "Shy-Drager syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 107 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02008721
(ClinicalTrials.gov)		January 20148/12/2013Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-ApproachDouble-blind, Randomised, Placebo-controlled Parallel Group Study to Investigate the Effect of EGCG Supplementation on Disease Progression of Patients With Multiple System Atrophy (MSA)Multiple System AtrophyDrug: EGCG as putative neuroprotective agent;Drug: PlaceboDr. Johannes LevinGerman Center for Neurodegenerative Diseases (DZNE);Deutsche Parkinson Vereinigung;Deutsche Stiftung Neurologie;ParkinsonFonds Deutschland gGmbHCompleted18 YearsN/ABoth92Phase 3Germany